Despite early and adequate antibiotic treatment, bacterial meningitis is an infection with a high mortality rate, particularly for very young and elderly patients. Furthermore, recovery is often associated with persistence of serious sequelae, e.g., hearing loss or other cranial nerve damage (12, 92) . Because of the often unfavorable course of meningitis, animal models were developed to obtain more insight into the pathophysiology of this infection and to determine whether modulation of the host responses affects the outcome (131) .
The pathophysiology of bacterial meningitis is summarized in the legend of Fig. 1 . Intact bacteria as well as cell wall products of gram-negative bacteria (GNB), i.e., lipopolysaccharide (LPS) and peptidoglycan, or products of gram-positive bacteria (GPB), e.g., peptidoglycan and lipoteichoic acids, but not the capsule polysaccharide, play an important role in inducing meningeal inflammation (14, 103, 123, 129, (137) (138) (139) 163) . Outer membrane protein A of Escherichia coli mediates the traversal of these bacteria across the blood-brain barrier (BBB) (93, 94) . LPS concentrations in cerebrospinal fluid (CSF) of patients with Haemophilus influenzae type b (Hib) meningitis correlate with clinical severity and neurological outcome (67) . Since bacterial products can be cytotoxic to neuronal cells they may play a role in the development of neurological sequelae (129) . Once the bacteria have entered the subarachnoidal space (SAS), leukocytes, endothelial cells, and other cells in the central nervous system (CNS) are stimulated to produce proinflammatory mediators such as cytokines and prostaglandins (38, 99, 102, 136, 142) , which leads to an increased permeability of the BBB ( Fig. 1) (13, 89, 103, 109, 113, 118, 135) . This last effect enhances the migration of leukocytes (1), i.e., granulocytes and monocytes, which can eliminate the bacteria in the SAS but can also harm the CNS (57, 127) . The increased permeability of the BBB also promotes leakage of plasma into the CNS, with development of an inflammatory exudate, cerebral edema, elevation of intracranial pressure, and alteration of cerebral blood flow ( Fig. 1) (90, 126, 134, 141, 143) .
The purpose of this review is to summarize current knowledge about modulation of the course of the inflammatory process during acute bacterial meningitis with nonantibiotic drugs or immunotherapy.
ROLE OF INFLAMMATORY MEDIATORS IN THE PATHOPHYSIOLOGY OF THE INFLAMMATORY REACTION
In this section the role of various proinflammatory and antiinflammatory cytokines and nitric oxide (NO) in the pathophysiology of bacterial meningitis will be discussed first since this is required for understanding the mode of intervention with adjunctive therapy. Proinflammatory mediators such as tumor necrosis factor alpha (TNF-␣), interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-8 (IL-8) and the anti-inflammatory mediators interleukin-10 (IL-10) and transforming growth factor-␤ (TGF-␤) are involved in the pathophysiology of bacterial meningitis (27, 77, 85, 91, 95, 132) . The early appearance of TNF-␣, IL-1, IL-6, and IL-8 in CSF prior to the increase of leukocytes shows that these cytokines are released from cells normally present in the CNS, such as endothelial cells, microglial cells, and astrocytes, which indicates that they play a role in the initial phase of the local inflammatory reaction (5, 11, 21, 156) . Next, the monocytes in the inflammatory exudate are the major origin of the cytokines. Anti-inflammatory cytokines, like IL-10 and TGF-␤, can mitigate the inflammatory process during bacterial meningitis by inhibiting the production of proinflammatory cytokines, e.g., TNF-␣ (Fig. 2) . In this respect, cytokines form a network which has stimulatory and inhibitory effects on the inflammatory process.
TNF-␣ is formed by a wide variety of cells, such as monocytes, macrophages, microglial cells, astrocytes, and endothelial cells (11) . During bacterial, but not viral meningitis, TNF-␣ is present in the CSF; high levels in CSF are associated with seizures, whereas high levels in serum are associated with a high mortality rate (4, 24, 32, 56, 58, 78, 80, 97, 146, 155, 156) . In vitro, TNF-␣ promotes inflammation in the SAS and can cause tissue damage of oligodendrocytes, astrocytes, neuronal cells, and myelin (33, 39, 99, 116, 129) .
IL-1 is formed by many kinds of cells, e.g., monocytes, macrophages, granulocytes, endothelial cells, microglial cells, and astrocytes (22) , and stimulates the production of other cytokines such as IL-6 (151) and TNF-␣ (41). In patients with bacterial meningitis IL-1 is present in the CSF, but not in the circulation, and high levels correlate with the development of neurological complications (58, 66, 73, 98) . IL-1 enhances BBB permeability for leukocytes and plasma, thus contributing to the development of an inflammatory exudate (96, 109) .
IL-6 is formed by monocytes, macrophages, endothelial cells, T lymphocytes, and fibroblasts. The production of this cytokine is stimulated by IL-1 and TNF (151) . The levels of IL-6 in the circulation and CSF are elevated during meningitis, and very high levels are associated with a fatal outcome (24, 36, 151, 156) .
IL-8 is formed by monocytes, macrophages, endothelial cells, and fibroblasts and is a chemotactic stimulus for neutrophils during an infection (1, 5, 40, 149) . LPS, TNF-␣, and IL-1 induce the production of IL-8 (6, 64) . During bacterial meningitis high levels of IL-8 are present in the CSF (34, 65, 115, 150) . However, two studies of patients with bacterial meningitis showed no relationship between IL-8 levels and granulocyte counts in CSF (34, 59) .
IL-10 is formed by T and B lymphocytes and monocytes and has an inhibitory effect on the production of proinflammatory cytokines such as TNF-␣ (20, 30, 61-63, 71, 144, 146, 161, 162) . IL-10 also inhibits the production of chemokines by leukocytes and down regulates the expression of intercellular adhesion molecule 1 and chemoattractant proteins by endothelial cells, thus inhibiting leukocyte migration to the site of the infection (44, 152) . In turn, TNF-␣ can induce the production of IL-10 upon stimulation with endotoxin (144, 162) . In patients with bacterial, but not viral, meningitis high levels of IL-10 are detectable in CSF (27, 49, 55, 146) and might be produced locally in the CNS by microglial cells and astrocytes, as demonstrated in mice (69) . TGF-␤ is produced by virtually all types of cells, including monocytes and endothelial cells (159) . This cytokine is an inhibitor of the production of TNF-␣, IL-1, and IL-6 by human monocytes (16, 72) . It also blocks the ability of interferon gamma (IFN-␥) to induce the formation of radical oxygen intermediates and reactive nitrogen intermediates by murine macrophages (23, 133) . For human monocytes, TGF-␤ is a potent chemoattractant (158) . In leukocytes of the CSF from patients with meningitis TGF-␤ has been demonstrated by in situ hybridization (86) .
NO is a highly reactive molecule produced by at least two major isoforms of NO-synthase: the constitutive form and the inducible form (iNOS) (70, 164) . In the CSF of patients with bacterial meningitis, nitrite, a stable metabolite of NO, is present and the level correlates with the level of TNF-␣ in the CSF of these patients (145, 153) . Proinflammatory mediators such as TNF-␣ and IL-1, which play an important role in the pathophysiology of bacterial meningitis, can induce iNOS and thus the production of NO locally by endothelial cells, astrocytes, microglial cells, neuronal cells, and granulocytes (18, 46, 51, 54, 70, 122) . In an experimental meningitis model, TNF-␣ injected into the cisterna magna induces production of NO, which in turn increases the intracranial pressure, reduces the oxygen uptake, increases the lactate concentration in CSF, and decreases the CSF/blood glucose ratio (141). It is not clear whether increased NO levels in the SAS have a beneficial or detrimental effect in meningitis patients. A positive effect of moderately elevated NO levels in CSF might be sealing of the vascular endothelial layer and subsequently inhibiting the leakage of plasma proteins via postcapillary venules and inhibiting adhesion of leukocytes to endothelial cells and thus their transendothelial migration to the CNS (50, 82) . High levels of NO can have a detrimental effect because of the neurotoxicity of NO (18, 83) .
EFFECT OF ANTIBIOTIC TREATMENT ON THE INFLAMMATORY PROCESS
Early and optimal treatment with antibiotics is the most effective intervention in bacterial meningitis. Nevertheless, the outcome may be fatal and survival may be accompanied by sequelae. Antibiotic treatment, especially with ␤-lactams, can also have a harmful effect because of the release of components of the bacterial cell wall into the SAS, which will enhance the inflammatory reaction (2, 28, 68, 74, 75, 130, 136) . After initiation of antibiotic treatment, increased levels of LPS in CSF have been shown in experimental and clinical meningitis (2, 3, 28, 67, 68, 74, 75, 130) . However, in CSF of rabbits with E. coli meningitis not treated with antibiotics, the levels of cell-free LPS are considerably higher than in antibiotic-treated animals (28) . Interaction of antibiotics with GPB can also lead to the release of bacterial cell wall products, e.g., lipoteichoic acids and peptidoglycans from pneumococci in the SAS, and thus enhance the inflammatory reaction (29, 37, 136, 138) . The data presently available do not justify a conclusion as to which ␤-lactam antibiotic used in the treatment of bacterial meningitis is the least active in vivo in the release of LPS.
ADJUNCTIVE THERAPY FOR INTERVENTION IN THE PATHOPHYSIOLOGY OF BACTERIAL MENINGITIS
The inflammatory response during meningitis can be modulated with drugs that affect the migration of leukocytes or inhibit the production of cytokines or prostaglandins (Fig. 2) . In this review these modalities will be discussed in relation to the pathophysiology of bacterial meningitis. (i) PTX. Pentoxifylline (PTX), a methylxanthine derivative, is a nonspecific inhibitor of intracellular phosphodiesterases, thus increasing the level of cyclic AMP (cAMP). PTX affects various functional properties of activated leukocytes and inhibits the production of TNF-␣ by monocytes after stimulation with LPS or GNB (25, 81, 107, 117, 121, 147, 149, 157, 165) (Fig. 2) . The mechanism by which PTX inhibits TNF-␣ production might be nonspecific via intracellular increase of the level of cAMP (10, 25, 117, 120) or more specific via inhibition of the transcription of TNF-␣ mRNA (35, 111, 120) . Although PTX is known for its inhibitory effect on TNF-␣, recent studies have shown a decrease in the release of IL-1 by human leukocytes (81, 121, 147) (Fig. 2) and microglial cells as well (17) , which is in contrast with earlier reports (26, 149) . Ex vivo experiments with blood leukocytes from healthy volunteers who had ingested PTX have shown an inhibitory effect of PTX on the release of IL-6 and IL-8 (81); however, other studies failed to confirm these data (17, 111, 149, 157, 165) . A stimulatory effect on the production of IL-10 by human leukocytes stimulated with GPB has also been demonstrated (148) . In rabbits with experimental meningitis, treatment with PTX markedly reduced the inflammation in the SAS but had no effect on the permeability of the BBB (104, 106) . These findings are encouraging since administration of this drug might decrease the inflammatory response in patients with meningitis, thus improving the prognosis. Lisofylline (LSF), a metabolite of PTX, is a new xanthine derivate that inhibits the intracellular production of phosphatidic acid (101, 119) . In vitro studies with P388 monocytic leukemia cells and human monocytes have shown that LSF inhibits the production of TNF-␣ and IL-1␤ (15, 148) but increases the production of IL-10 by human monocytes stimulated by GPB (148) . Preliminary results of phase III studies have shown that LSF at concentrations in serum higher than those maximally tolerated with PTX gave no serious adverse effects (100a). For adjunctive treatment of meningitis, LSF might be preferable to PTX because of its low toxicity.
(ii) Thalidomide. Thalidomide (␣-N-pthalimidoglutarimide) is an anti-inflammatory and immunosuppressive agent that inhibits the production of TNF-␣ by LPS-stimulated monocytes but does not affect the production of IL-1␤ and IL-6 (108). This process is independent of the upregulation of IL-10 production by these cells. The decrease of TNF-␣ production is not complete, thus leaving intact cell-mediated immunity, which requires TNF-␣. In rabbits with acute meningitis induced by Mycobacterium bovis BCG, intracisternally (i.c.) injected oral treatment with thalidomide reduced the TNF-␣ concentration in the CSF rapidly and the survival of the animals was significantly increased (43a). Perhaps thalidomide or its analogs, which are currently synthesized, can be used to modulate the course of acute meningitis in humans.
(iii) GC. Glucocorticosteroids (GC) inhibit the production of cytokines such as IL-1, IL-6, IL-8, and TNF-␣ or prostaglandins by human monocytes (45, 114, 147, 149, 154) and microglial cells (17) or in patients treated with GC (77, 79) (Fig. 2) . The production of IL-10 by human monocytes can either be increased or decreased, which depends on whether GRB or GNB are used as stimuli (147) (personal observation). The exact mechanism of action of GC on cytokine production is not yet certain but might be based on inhibition of transcription factors (7) or inhibition of the translation of mRNA (35, 45, 100) . Upon stimulation of cells to synthesize cytokines, nuclear factor kappa B (NFB) translocates from the cytoplasm to the nucleus, where it induces transcription of various immunoregulatory genes. Stimulation of cytokine production in the presence of dexamethasone (DXM) leads to increased synthesis of IB␣ protein, the cytoplasmic inhibitor of NFB. Association of IB␣ with NFB leads to inactive cytoplasmatic complexes, thus inhibiting translocation of NFB to the nucleus and consequently the synthesis of cytokines (112) . In VOL. 64, 1996 MINIREVIEW 4885 animals with bacterial meningitis, these drugs have a beneficial effect on the inflammatory response in the CNS with respect to the development of brain edema (68, 75, 76, 105, 124, 128) and leukocyte numbers in CSF, possibly via inhibition of leukocyte adhesion to endothelial cells (60) . Several clinical, prospective studies have addressed the issue of adjunctive GC therapy in the management of bacterial meningitis in children ( Table 1 ). The first controlled trials of GC in the sixties showed no improvement in the long-term outcome of bacterial meningitis, although limited attention was paid to the evaluation of hearing impairment (9, 19) . New insights into the pathophysiology of bacterial meningitis renewed interest in immunomodulation of the inflammatory response in the CSF. Since 1988, several trials with GC as adjunctive therapy in the treatment of bacterial meningitis have been performed. Most of these studies showed at least favorable trends in the course and outcome of bacterial meningitis in children treated with GC compared with placebo-treated or untreated patients. The patients became afebrile sooner; follow-up examination of the CSF showed more rapid normalization of the number of leukocytes and concentrations of protein and glucose, and the frequency of neurological sequelae or severe hearing loss was reduced consistently. The majority of the patients were children suffering from meningitis caused by Hib; other cases were caused by Streptococcus pneumoniae or Neisseria meningitidis.
In the clinical trials the onset of DXM treatment ranged from 20 min before antibiotic administration to 24 h after initiation of antibiotic treatment. However, experimental studies with animals showed a beneficial effect only when DXM was given before antibiotic treatment had been started (75) . This might explain the lack of an effect of DXM on hearing impairment in the various studies. Since the introduction of the conjugate vaccine against Hib, the number of patients with Hib meningitis has declined dramatically (89a). Therefore, in the future most cases of bacterial meningitis will be caused by S. pneumoniae or N. meningitidis. To establish whether GC are also beneficial as adjunctive therapy in the treatment of meningitis caused by these bacteria, further controlled trials are required. At present, there is no official recommendation that adjunctive therapy with DXM be used in adults with bacterial meningitis, but trials are in progress.
(iv) Immunotherapy. Immunotherapy of bacterial meningitis has not yet reached the level of clinical trials. However, several animal studies have been performed. When rabbits with sterile meningitis induced by an i.c. injection of Hib lipooligosaccharide (LOS) were treated with soluble TNF receptor and IL-1 receptor antagonist i.c., the leukocyte number in CSF dropped significantly, only at 24 h, but not the other parameters of inflammation (87) . Monoclonal antibodies (MAb) against LPS, applied i.c., inhibited the development of brain edema in rabbits with E. coli meningitis (130) . The antiinflammatory cytokine IL-10 given i.c. or intravenously (i.v.) to rabbits with meningitis induced by Hib, Hib LOS, or Listeria monocytogenes reduced the amount of TNF-␣ and the inflammatory response in CSF significantly. Treatment of these animals with IL-10 together with DXM or the combination IL-10, DXM, and ceftriaxone or ampicillin had a greater effect (88) . TGF-␤ injected intraperitoneally had a beneficial effect in experimental pneumococcal meningitis by inhibiting cerebrovascular changes and the formation of brain edema (91) . In mice, deficient in endothelial selectins, with cytokine-induced meningitis the influx of leukocytes in the CSF was decreased (125) . This indicates that blocking of selectins with MAb may provide an approach for adjunctive therapy. Another approach to modulate the transendothelial migration of leukocytes is the use of MAb against leukocyte-specific adhesion molecules (␤ 2 integrins) (8) . i.v. injection of MAb against the common ␤ chain of ␤ 2 integrins (anti-CD18) inhibited the recruitment of leukocytes into the SAS, the increase of protein in CSF, and the development of brain edema in rabbits with meningitis induced by live S. pneumoniae, N. meningitidis, Hib, pneumococcal cell wall, or LPS (109, 140) . Similar effects were observed in rabbits with LOS-induced meningitis or live Hib meningitis treated with anti-CD18 MAb i.v.. Treatment of these rabbits with anti-CD18 MAb together with DXM attenuated the inflammatory response in the SAS more markedly (105) . At present, however, anti-CD18 MAb that can be applied to humans is not yet available. Taken together, immunotherapy alone or in combination with DXM of patients with bacterial meningitis might be promising as an adjunct to antibiotics. However, clinical trials must be performed to establish whether immunotherapy provides a better outcome than adjunctive therapy with DXM alone.
SUMMARY
Since meningitis is an inflammation in a closed space, i.e., the skull, without any possibility for expansion, deleterious effects on the CNS can occur rather rapidly. Bacteria and bacterial products stimulate the production of proinflammatory and anti-inflammatory cytokines and prostaglandins in the CNS, all of which have an effect on the occurrence of inflammatory exudate. Therefore, it might be preferable to choose antibiotics that cause the least release of cell wall components in order to avoid the production of proinflammatory mediators. Many modalities to limit the inflammatory process have been studied. Immunotherapy with MAb or anti-inflammatory cytokines are successful in experimental meningitis but have not yet reached the level of clinical research. In experimental meningitis some nonsteroidal anti-inflammatory drugs (NSAIDs) have shown beneficial effects on CNS inflammation while others have not (42, 136, 142) . At the moment it is unpredictable which NSAIDs can safely be administered to patients with meningitis. PTX inhibits the production of various cytokines and has a favorable effect on the course of experimental meningitis but, as far as we know, has not yet been used in patients with meningitis. Studies with experimental meningitis and clin- ical trials have shown that GC are the most promising drugs for adjunctive therapy. DXM has a beneficial effect on the neurologic and audiologic outcome of the disease. Preferably, the first dose of DXM must be administered before or with the first dose of the antibiotic. Since in experimental meningitis, PTX reduced the inflammation in the SAS markedly, it may be assumed that DXM in combination with PTX would have a favorable result through the inhibition of proinflammatory mediators. The fact remains, however, that more clinical studies with various adjunctive drugs alone and in combination must be performed before firm recommendations can be made.
